AAAAAA

   
Results: 1-8 |
Results: 8
ELIMINATION AND BIOCHEMICAL RESPONSES TO INTRAVENOUS ALENDRONATE IN POSTMENOPAUSAL OSTEOPOROSIS
Authors: KHAN SA KANIS JA VASIKARAN S KLINE WF MATUSZEWSKI BK MCCLOSKEY EV BENETON MNC GERTZ BJ SCIBERRAS DG HOLLAND SD ORGEE J COOMBES GM ROGERS SR PORRAS AG
Citation: Sa. Khan et al., ELIMINATION AND BIOCHEMICAL RESPONSES TO INTRAVENOUS ALENDRONATE IN POSTMENOPAUSAL OSTEOPOROSIS, Journal of bone and mineral research, 12(10), 1997, pp. 1700-1707
INTRAARTERIAL SUBSTANCE-P MEDIATED VASODILATATION IN THE HUMAN FOREARM - PHARMACOLOGY, REPRODUCIBILITY AND TOLERABILITY
Authors: NEWBY DE SCIBERRAS DG MENDEL CM GERTZ BJ BOON NA WEBB DJ
Citation: De. Newby et al., INTRAARTERIAL SUBSTANCE-P MEDIATED VASODILATATION IN THE HUMAN FOREARM - PHARMACOLOGY, REPRODUCIBILITY AND TOLERABILITY, British journal of clinical pharmacology, 43(5), 1997, pp. 493-499
INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HTID AGONIST (VOL 43, PG 49, 1997)
Authors: SCIBERRAS DG POLVINO WJ GERTZ BJ CHENG HY STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T
Citation: Dg. Sciberras et al., INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HTID AGONIST (VOL 43, PG 49, 1997), British journal of clinical pharmacology, 43(4), 1997, pp. 450-450
INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HT1D AGONIST
Authors: SCIBERRAS DG POLVINO WJ GERTZ BJ CHENG HY STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T
Citation: Dg. Sciberras et al., INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HT1D AGONIST, British journal of clinical pharmacology, 43(1), 1997, pp. 49-54
THE EFFECTS OF A PERIPHERALLY SELECTIVE ALPHA-2-ADRENOCEPTOR ANTAGONIST, MK-467, ON THE METABOLIC AND CARDIOVASCULAR-RESPONSE TO EXERCISE IN HEALTHY MAN
Authors: SCIBERRAS DG REED JW ELLIOTT C BLAIN PG GOLDBERG MR
Citation: Dg. Sciberras et al., THE EFFECTS OF A PERIPHERALLY SELECTIVE ALPHA-2-ADRENOCEPTOR ANTAGONIST, MK-467, ON THE METABOLIC AND CARDIOVASCULAR-RESPONSE TO EXERCISE IN HEALTHY MAN, British journal of clinical pharmacology, 37(1), 1994, pp. 39-44
L-692,429, A NONPEPTIDE GROWTH-HORMONE (GH) SECRETAGOGUE, REVERSES GLUCOCORTICOID SUPPRESSION OF GH SECRETION
Authors: GERTZ BJ SCIBERRAS DG YOGENDRAN L CHRISTIE K BADOR K KRUPA D WITTREICH JM JAMES I
Citation: Bj. Gertz et al., L-692,429, A NONPEPTIDE GROWTH-HORMONE (GH) SECRETAGOGUE, REVERSES GLUCOCORTICOID SUPPRESSION OF GH SECRETION, The Journal of clinical endocrinology and metabolism, 79(3), 1994, pp. 745-749
CLINICAL-PHARMACOLOGY OF ANGIOTENSIN AND BRADYKININ IN HUMAN FOREARM VASCULATURE
Authors: RITTER JM COCKCROFT JR SCIBERRAS DG GOLDBERG MR
Citation: Jm. Ritter et al., CLINICAL-PHARMACOLOGY OF ANGIOTENSIN AND BRADYKININ IN HUMAN FOREARM VASCULATURE, Journal of hypertension, 11, 1993, pp. 59-61
COMPARISON OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION WITH ANGIOTENSIN-II RECEPTOR ANTAGONISM IN THE HUMAN FOREARM
Authors: COCKCROFT JR SCIBERRAS DG GOLDBERG MR RITTER JM
Citation: Jr. Cockcroft et al., COMPARISON OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION WITH ANGIOTENSIN-II RECEPTOR ANTAGONISM IN THE HUMAN FOREARM, Journal of cardiovascular pharmacology, 22(4), 1993, pp. 579-584
Risultati: 1-8 |